Table 1.
Baseline characteristics of included studies and patients.
| Trial | Year | Country | Sample size | Type and dose of monotherapy | Dual therapy group | Follow up‐ months | CHA2 DS2‐VASc scorea | CHADS2 score | HAS‐BLED score | Age‐ mean ± SD | Males‐ n (%) | Paroxysmal AF‐ n (%) | Persistent AF‐ n (%) | Permanent AF‐ n (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OAC monotherapy | Dual therapy | OAC Monotherapy | Dual therapy | OAC Monotherapy | Dual therapy | OAC Monotherapy | Dual therapy | OAC Monotherapy | Dual therapy | OAC Monotherapy | Dual therapy | |||||||||
| AFIRE | 2019 | Japan | 1107 | 1108 | Rivaroxaban 15 mg | Rivaroxaban plus Aspirin or P2Y12 inhibitor | 24.1 | 4 | 2 | 2 | 74.3 ± 8.3 | 74.4 ± 8.2 | 875 (79.0) | 876 (79.1) | 596 (53.8) | 580 (52.3) | 164 (14.8) | 175 (15.8) | 347 (31.3) | 353 (31.9) |
| OAC‐ALONE | 2019 | Japan | 344 | 346 | Warfarin or DOAC | Warfarin or DOAC plus Aspirin or clopidogrel | 30 | 4.6 | 2.5 | 2 | 74.9 ± 0.4 | 75.2 ± 0.4 | 294 (85.5) | 294 (85.0) | 158 (45.9) | 143 (41.3) | 27 (7.9) | 23 (6.7) | 159 (46.2) | 180 (52.0) |
| EPIC‐CAD | 2024 | South Korea | 524 | 516 | Edoxaban 60 mg once daily | Edoxaban plus Aspirin or a P2Y12 inhibitor | 12 | 4 | 2 | 2 | 71.7 ± 8.0 | 72.5 ± 8.4 | 396 (75.6) | 406 (78.7) | 292 (55.7) | 283 (54.8) | 232 (44.3) | 233 (45.2) | 232 (44.3) | 233 (45.2) |
Note: AFIRE, atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease; OAC‐ALONE, the optimizing antithrombotic care in patient with atrial fibrillation and coronary stent; EPIC‐CAD, edoxaban versus edoxaban with antiplatelet agent in patients with atrial fibrillation and chronic stable coronary artery disease; OAC, oral anticoagulant; n, number; AF, atrial fibrillation; CHADS2, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or TIA or thromboembolism (doubled), CHA2DS2‐VASc, congestive heart failure or left ventricular dysfunction Hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)‐vascular disease, age 65–74, sex category, HAS‐BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, Labile INR, elderly, drugs/alcohol concomitantly, DOAC: direct oral anticoagulant, n: number.
The values are given as mean.